Evonile Pharma Limited (formerly Novartis India Limited) has announced a board meeting scheduled for October 8, 2026, to deliberate on raising funds through a rights issue of equity shares. With a face value of ₹5 per share, this potential capital infusion is a significant development for existing stakeholders. The company also confirmed that its trading window remains closed for insiders until November 5, 2026, pending the release of quarterly financial results.
Evonile Pharma to Consider Rights Issue in October Board Meeting
- Date of Board Meeting: October 8, 2026
- Security Face Value: ₹5 per share
Reader Takeaway: The rights issue aims to raise capital, but investors should await the entitlement ratio and issue price.
What just happened
Evonile Pharma Limited, previously known as Novartis India Limited, has informed the stock exchanges that its Board of Directors will convene on October 8, 2026. The primary objective of this meeting is to evaluate and approve a proposal to raise capital via a rights issue of equity shares. The shares carry a face value of ₹5 each. Any final execution remains subject to necessary regulatory and statutory clearances.
Why this matters
A rights issue is a corporate action that allows existing shareholders to purchase additional shares, often at a discount. For retail investors, this is a critical event as it can lead to equity dilution if the issue size is large. Shareholders should pay close attention to the upcoming board announcement, which is expected to disclose the specific entitlement ratio, the offer price, and the record date, which will dictate who is eligible to participate.
Trading Window Update
The company confirmed that the trading window for designated persons and insiders remains closed. This period, which commenced on October 1, 2026, will remain in force until 48 hours after the company declares its unaudited financial results for the quarter ended September 30, 2026. This closure is scheduled to end on November 5, 2026. Since the board meeting falls within this window, the company does not need to issue a fresh closure notification.
What to track next
Investors should keep an eye on the outcome of the October 8 board meeting. Key details to watch for include the total amount the company intends to raise, the purpose of the funds (such as debt repayment or expansion), and whether the rights issue is priced at a premium or a discount to the current market price.